Bayer announced that the Chinese National Medical Products Administration (NMPA) has granted marketing authorization for finerenone under the brand name Kerendia.
Kerendia (10 mg or 20 mg), a non-steroidal, selective mineralocorticoid receptor (MR) antagonist, is indicated for the treatment of chronic kidney disease (CKD) (eGFR of = 25 to 75 mL/min/1.73 m2 with albuminuria) associated with type 2 diabetes (T2D) in adults, to reduce the risk of sustained eGFR decline and end-stage kidney disease.
The approval of Kerendia in China is based on the results of the pivotal phase III study FIDELIO-DKD, presented at the American Society of Nephrology
